Print this page    •   Back to Web version of article

Approved Antiretroviral Drugs

Winter 2005/2006

Generic (Common) NameBrand NameCompanyYear Approved
Protease Inhibitors (PIs)
amprenavirAgeneraseGlaxoSmithKline1999; discontinued 2004
atazanavirReyatazBristol-Myers Squibb2003
fosamprenavirLexiva (U.S.); Telzir (Europe)GlaxoSmithKline2003
lopinavir/ritonavirKaletraAbbott2000; Meltrex formulation 2005
saquinavirInvirase (hard-gel)
Fortovase (soft-gel)
1997; withdrawn 2005
tipranavirAptivusBoehringer Ingelheim2005
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
didanosine (ddI)VidexBristol-Myers Squibb1989; extended release Videx EC 2000
emtricitabine (FTC)EmtrivaGilead2003
lamivudine (3TC)EpivirGlaxoSmithKline1995
stavudine (d4T)ZeritBristol-Myers Squibb1994
zalcitabine (ddC)HividRoche1992; withdrawn 2005
zidovudine (AZT)RetrovirGlaxoSmithKline1987
tenofovir DFVireadGilead2002
NRTI Fixed-Dose Combinations
lamivudine/abacavirEpzicom (U.S.); Kivexa (Europe)GlaxoSmithKline2004
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
efavirenzSustiva (U.S.); Stocrin (elsewhere)Bristol-Myers Squibb1998
nevirapineViramuneBoehringer Ingelheim1996
Entry/Fusion Inhibitors
enfuvirtide (T-20)FuzeonTrimeris2003

Back to the SFAF BETA Winter 2005/2006 contents page.

This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.